Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $31.67 Consensus PT from Analysts

by · The Cerbat Gem

Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) has been assigned an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $31.6667.

A number of research firms have recently weighed in on AVTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Tuesday, October 14th. BTIG Research restated a “buy” rating and issued a $40.00 price target on shares of Avalo Therapeutics in a research note on Monday, September 29th. Cantor Fitzgerald started coverage on shares of Avalo Therapeutics in a report on Friday, August 15th. They issued an “overweight” rating on the stock. TD Cowen initiated coverage on shares of Avalo Therapeutics in a research note on Friday, September 5th. They set a “buy” rating for the company. Finally, HC Wainwright boosted their price target on shares of Avalo Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 17th.

Get Our Latest Stock Report on AVTX

Avalo Therapeutics Price Performance

Shares of NASDAQ AVTX opened at $17.56 on Friday. The firm has a fifty day moving average price of $16.10 and a 200-day moving average price of $10.29. The stock has a market cap of $318.36 million, a PE ratio of -3.28 and a beta of 0.84. Avalo Therapeutics has a 1 year low of $3.39 and a 1 year high of $19.41.

Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($2.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.52). On average, research analysts expect that Avalo Therapeutics will post -19.07 EPS for the current year.

Hedge Funds Weigh In On Avalo Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cantor Fitzgerald L. P. bought a new stake in Avalo Therapeutics in the 3rd quarter worth approximately $1,083,000. Velan Capital Investment Management LP boosted its position in shares of Avalo Therapeutics by 70.1% during the 3rd quarter. Velan Capital Investment Management LP now owns 263,642 shares of the company’s stock valued at $3,351,000 after acquiring an additional 108,670 shares during the last quarter. Prelude Capital Management LLC purchased a new position in shares of Avalo Therapeutics in the third quarter valued at $313,000. Nantahala Capital Management LLC increased its position in Avalo Therapeutics by 24.1% in the third quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock worth $15,697,000 after purchasing an additional 240,000 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in Avalo Therapeutics during the third quarter valued at $1,747,000. 87.06% of the stock is owned by institutional investors.

Avalo Therapeutics Company Profile

(Get Free Report)

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.

Featured Articles